Journal of Clinical Oncology
Articles in this Issue
Cross-sectional study on the impact of receiving potentially sensitive test results online on the emotional health of patients with breast cancer.
1575 Background: Internet has changed the way people communicate. In healthcare, patients have now easy access to their test results online; however, this...
Distinct margin mutation dissemination patterns in <i>EGFR</i> L858R-mutated lung cancers.
e20046 Background: It has been revealed that non-small-cell lung cancer (NSCLC) classified as R0 resection margins under microscopic assessment still cont...
The role of the Colorectal Cancer Alliance’s digital screening quiz in advancing CRC screening.
e22526 Background: The Colorectal Cancer Alliance developed a digital Screening Quiz and live navigation model to promote colorectal cancer (CRC) screenin...
RC48-ADC combined with radiotherapy and immunotherapy as salvage therapy for advanced solid tumors with HER2 expression: A multicenter, phase II trial.
3032 Background: Antibody-drug conjugates (ADC) have demonstrated efficacy in treating tumors with HER2 over expression. However, the clinical benefits of...
Impact of autonomic dysfunction on function, toxicity, and survival in patients with lymphoma treated with CART.
e19010 Background: Autonomic dysfunction (AD) is a phenomenon that has been identified in subsets of patients (pts) treated with chimeric antigen receptor...
Underreporting of health-related quality of life in trials of matched targeted therapies for advanced or metastatic cancer.
e23188 Underreporting of Health-Related Quality of Life in Trials of Matched Targeted Therapies for Advanced or Metastatic Cancer Background:...
The Indian cancer genome landscape: Pathogenic alterations and emerging therapeutic targets.
e15094 Background: Comprehensive genomic profiling (CGP) is essential for identifying actionable and prognostic biomarkers in oncology practice. This stud...
Prognostic impact of histological subtypes in non-muscle-invasive UTUC: Propensity matched analysis.
4592 Background: Upper tract urothelial carcinoma (UTUC) is a rare malignancy with poor outcomes. While histological subtypes are known to influence bladd...
An oral prostate cancer RIPTACtherapeutic in phase 1 for metastatic castrate resistant prostate cancer (mCRPC).
TPS5115 Background: New therapies are urgently needed to treat prostate cancer, especially for patients progressing on existing drugs that inhibit the act...
Preclinical efficacy of PR115002, a novel sortilin-targeting peptide-drug conjugate, in platinum-resistant ovarian cancer.
e17559 Background: Approximately 70%-80% of individuals diagnosed with ovarian cancer (OC) experience disease recurrence, with a significant proportion ul...
Predicting immunotherapy response in advanced solid tumors using quantitative imaging features from CD8 PET/CT exams.
3098 Background: CD8-PET/CT imaging with 89 Zr crefmirlimab berdoxam (ImaginAb, Inc), which targets CD8-expressing T-lymphocytes,...
Trends in place of death among breast cancer patients in the United States (1999–2023): A 25-year analysis of racial and regional disparities.
11152 Background: Breast cancer is the second most prevalent cancer among women in the United States, associated with significant morbidity and mortality...
Circulating tumor DNA profiling of patients with metastatic luminal HER2-low and HER2-0 breast cancer via next-generation sequencing.
e13090 Background: Despite substantial progress in the treatment of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer, a signif...
Systematic review and meta-analysis of neoadjuvant anti–PD-(L)1 inhibitors in head and neck squamous cell carcinoma.
e18069 Background: Neoadjuvant PD-(L)1 inhibitors have emerged as a promising therapeutic option in multiple cancer types, including head and neck squamou...
Delivery of B7H3-targeted CAR-T cells in injectable silk hydrogels and effects on the efficacy in treating solid tumors.
e15182 Background: Chimeric antigen receptor (CAR)-T cell immunotherapy has been shown to be highly efficacious in the treatment of blood cancers, but rem...
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA.
5512 Background: DUO-E (NCT04269200) showed statistically significant and clinically meaningful progression-free survival...
Evaluation of sacituzumab-induced severe or febrile neutropenia and G-CSF utilization and cost for advanced HER2- breast cancer.
e23259 Background: Sacituzumab govitecan-hziy (Saci) is an antibody-drug conjugate approved for patients (pts) with unresectable or metastatic triple-nega...
Pembrolizumab and lenvatinib in the treatment of recurrent, platinum-resistant ovarian carcinoma: A single institution experience.
e17612 Background: Advanced stage ovarian carcinoma has a poor prognosis with recurrence rates of more than 80% and a 5-year survival of approximately 36-...
Demographic and regional trends in cardiovascular disease and Hodgkin lymphoma–related mortality in the United States: A CDC WONDER perspective (1999-2020).
e19039 Background: Cardiovascular diseases (CVDs) are significant and burdensome complications of Hodgkin lymphoma (HL), contributing to increased mortali...
Safety and tolerability of intraventricular CARv3-TEAM-E T cells following lymphodepleting chemotherapy in recurrent glioblastoma: INCIPIENT trial.
2017 Background: CAR T therapy is a novel, promising approach in glioblastoma (GBM) but tumor heterogeneity can limit efficacy when a single antigen is ta...
Adaptive AI-driven clinical decision-making in oncology through digital twins and large-scale imaging biomarkers.
e13698 Background: Small deviations in clinical attributes particularly biomarkers play a crucial role in oncology disease staging, affecting prognosis, d...
Comparative meta-analysis of cisplatin dosing schedules in definitive chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma.
e18063 Background: Cisplatin-based chemoradiotherapy is the standard for locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC), but the...
Impact of histological subtypes in patients receiving first-line treatment with enfortumab vedotin/pembrolizumab in advanced metastatic urothelial cancer.
4575 Background: Metastatic urothelial carcinoma (mUC) represents a challenging clinical entity with significant morbidity and mortality. Enfortumab Vedot...
Predictors of septic shock among BCR/ABL-positive chronic myeloid leukemia patients admitted for sepsis: A nationwide study and analysis.
e18569 Background: Cancer patients, especially those with chronic myeloid leukemia (CML), are susceptible to infections and develop sepsis, which can lead...
Predictive and prognostic impacts of SCLC comprehensive index (SCI) in extensive-stage small-cell lung cancer (ES-SCLC) treated with chemo-immunotherapy.
8100 Background: First-line (1L) chemo-immunotherapy is standard of care for ES-SCLC with improved survival outcomes (IMpower133 and CASPIAN). However, th...